[HTML] nejm.org

[HTML][HTML] Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer

M Gnant, F Fitzal, G Rinnerthaler… - … England Journal of …, 2021 - Mass Medical Soc
Background For postmenopausal women with hormone-receptor–positive breast cancer, the
most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear …
被引用次数：117 相关文章

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

M Gnant, F Fitzal, G Rinnerthaler… - NEW ENGLAND …, 2021 - pure.pmu.ac.at
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. — PMU
Forschungsportal Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt …

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

M Gnant, F Fitzal, G Rinnerthaler… - The New England …, 2021 - europepmc.org
Background For postmenopausal women with hormone-receptor-positive breast cancer, the
most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear …

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

M Gnant, F Fitzal, G Rinnerthaler… - The New England …, 2021 - pubmed.ncbi.nlm.nih.gov
Background For postmenopausal women with hormone-receptor-positive breast cancer, the
most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear …

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

M Gnant, F Fitzal, G Rinnerthaler… - NEW ENGLAND …, 2021 - pure.pmu.ac.at
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. — PMU
Research Portal Skip to main navigation Skip to search Skip to main content PMU Research …